|Bid||282.48 x 100|
|Ask||282.82 x 100|
|Day's Range||281.84 - 283.52|
|52 Week Range||244.28 - 333.65|
|PE Ratio (TTM)||17.68|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A biotech breakout may be fueled by positive medical data and earnings
At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.
Novartis reported smaller earnings and revenue declines for Q2 than expected. Johnson & Johnson topped on earnings but fell just shy on revenue.